Lenka Besse

Masaryk University

Czech Republic

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Ana Slipicevic

SWEDEN

View details

Arun Wiita

Associate Professor

University of California, San Francisco

UNITED STATES

View details

Lorenzo Prever

University of Turin

ITALY

View details

Justin Eyquem

Assistant Professor

University of California, San Francisco

UNITED STATES

View details

Marc Pilon

Prof Genetics

University of Gothenburg

SWEDEN

View details

ELISABETTA MEREU

University of Turin

ITALY

View details

Corynn Kasap

University of California, San Francisco

UNITED STATES

View details

Juho Miettinen

University of Helsinki

FINLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lenka Besse

Research Interests

Explore related searches

Contact this professor

Articles (17)

Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens.

Targeting proteostasis in multiple myeloma through inhibition of LTK.

Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA).

Establishment of cancer immunotherapy in vitro model

HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.

High-dose carfilzomib achieves superior anti-tumor activity over lowdose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex

A replicating LCMV-based vaccine for the treatment of solid tumors.

Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.

Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors

Treatment with HIV-protease inhibitor nelfinavir identifies membrane lipid composition and fluidity as a therapeutic target in advanced multiple myeloma

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma

High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors

Novel peptide-drug conjugate melflufen efficiently eradicates bortezomib-resistant multiple myeloma cells including tumor-initiating myeloma progenitor cells

Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs

Collaborators (8)

Ana Slipicevic

Arun Wiita

Lorenzo Prever

Justin Eyquem

Marc Pilon

ELISABETTA MEREU

Corynn Kasap

Juho Miettinen

Make your next move.